Table 2 GSTP1 allele frequencies and BC HR in BRCA1 and BRCA2 carriers (adjusted for origin, Ashkenazi vs non-Ashkenazi)a

From: Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers

 

BRCA1 (n =228)

BRCA2 (n =90)

GSTP1

BC− ( n =78) no. (%)

BC+ ( n =150) no. (%)

Breast cancer HR (95% CI, P)

BC− ( n =29) no. (%)

BC+ ( n =61) no. (%)

Breast cancer HR (95% CI, P)

Ile/Ile

53 (67.9)

86 (57.3)

1

22 (75.9)

35 (57.4)

1

Age at BC

 

40.5 years

  

46.6 years

 

Ile/Val

22 (28.2)

54 (36)

1.22 (0.87–1.72, P=0.24)

7 (24.1)

20 (32.8)

1.50 (0.86–2.59, P=0.15)

Age at BC

 

42.6 years

  

42.6 years

 

Val/Val

3 (3.9)

10 (6.7)

1.38 (0.71–2.70, P=0.15)

0

6 (9.8)

3.20 (1.26–8.09, P=0.01)

Age at BC

 

40.1 years

  

41.2 years

 
  1. BC−, no BC; BC+, with BC; CI, confidence interval; HI, hazard ratio.
  2. aCompound heterozygotes were excluded from these analyses.
Back to article page